Pfizer Ltd
NSE:PFIZER
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3 913.75
5 889
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Pfizer Ltd
Income from Continuing Operations
Pfizer Ltd
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Pfizer Ltd
NSE:PFIZER
|
Income from Continuing Operations
₹8.4B
|
CAGR 3-Years
11%
|
CAGR 5-Years
11%
|
CAGR 10-Years
14%
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Income from Continuing Operations
₹57.4B
|
CAGR 3-Years
23%
|
CAGR 5-Years
22%
|
CAGR 10-Years
15%
|
|
|
Cipla Ltd
NSE:CIPLA
|
Income from Continuing Operations
₹54.5B
|
CAGR 3-Years
27%
|
CAGR 5-Years
24%
|
CAGR 10-Years
12%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Income from Continuing Operations
₹104.2B
|
CAGR 3-Years
35%
|
CAGR 5-Years
59%
|
CAGR 10-Years
10%
|
|
|
Lupin Ltd
NSE:LUPIN
|
Income from Continuing Operations
₹43.5B
|
CAGR 3-Years
271%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
7%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Income from Continuing Operations
₹21.4B
|
CAGR 3-Years
39%
|
CAGR 5-Years
13%
|
CAGR 10-Years
4%
|
|
Pfizer Ltd
Glance View
Pfizer Ltd., a giant in the pharmaceutical industry, has woven its identity deeply into the fabric of healthcare innovation. Established initially to create chemical compounds, it evolved into a pharmaceutical pioneer through a series of strategic developments and acquisitions. Headquartered in New York, the company has a sprawling international presence, with an intricate network of research facilities, manufacturing plants, and marketing offices spread across the globe. This global footprint empowers Pfizer to leverage diverse talent and resources, driving innovation and efficiency. At the core of Pfizer’s operations is its research and development engine, a crucial element that churns out new medicines and therapies. By investing heavily in R&D, absorbing over $8 billion annually, the company relentlessly pursues breakthroughs in areas such as oncology, vaccines, rare diseases, and primary care, consistently bringing advanced treatments from laboratories to clinics. The way Pfizer sustains its financial health is as much about strategic foresight as it is about scientific prowess. Its revenue streams are crafted through a mix of patent-protected pharmaceuticals, consumer health products, and vaccines. The blockbuster drug era, epitomized by the success of Lipitor, showcased its capability to capture market leadership efficiently. More recently, Pfizer's collaboration with BioNTech on the COVID-19 vaccine highlighted its agility and strategic partnerships. Such initiatives solidify its position in the market and open lucrative opportunities. Beyond products, Pfizer employs a robust marketing strategy and leverages an extensive distribution network to ensure these innovations reach a global clientele efficiently. Through a combination of smart financial management, cutting-edge research, and decisive partnerships, Pfizer Ltd. has positioned itself as a towering figure in the pharmaceutical landscape, capable of responding to global health challenges while ensuring sustainable growth.
See Also
What is Pfizer Ltd's Income from Continuing Operations?
Income from Continuing Operations
8.4B
INR
Based on the financial report for Sep 30, 2025, Pfizer Ltd's Income from Continuing Operations amounts to 8.4B INR.
What is Pfizer Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
14%
Over the last year, the Income from Continuing Operations growth was 36%. The average annual Income from Continuing Operations growth rates for Pfizer Ltd have been 11% over the past three years , 11% over the past five years , and 14% over the past ten years .